Listen "NeuroPace CEO resigns, former Depuy Synthes sales rep accused of defrauding hospital"
Episode Synopsis
Microbot Medical's completion of a pre-clinical study for its endovascular surgical robot signifies a significant milestone for the company. Fast Five hosts Danielle Kirsh and Sean Whooley explain what the surgical robot does and what the outcome of the pre-clinical study was.
The FDA clearance of Boston Scientific's Embold Soft & Packing coils demonstrates the company's commitment to expanding its portfolio of innovative solutions for embolization procedures. Hear about what the coils are designed for and how it streamlines hospital workflows on today's episode.
Integra Lifesciences' completion of enrollment in the DuraSorb monofilament mesh IDE study is a significant step toward gathering valuable clinical data for this product. Whooley details what the study will evaluate and how optimistic are executives at the company.
Federal prosecutors claim a former DePuy Synthes sales representative defrauded an undisclosed Boston area hospital, with hundreds of thousands of dollars worth of spine products involved. Kirsh and Whooley share what the sales representative is accused of, how it allegedly benefitted the sales rep and DePuy Synthes' response.
The resignation of NeuroPace's CEO and the appointment of a former Integer executive as his successor mark a significant leadership change within the company. Whooley and Kirsh discuss the details behind the resignation and who is taking over the corner office.
Check out the show notes for links to the stories we discussed today at MassDevice.com/podcast.
The FDA clearance of Boston Scientific's Embold Soft & Packing coils demonstrates the company's commitment to expanding its portfolio of innovative solutions for embolization procedures. Hear about what the coils are designed for and how it streamlines hospital workflows on today's episode.
Integra Lifesciences' completion of enrollment in the DuraSorb monofilament mesh IDE study is a significant step toward gathering valuable clinical data for this product. Whooley details what the study will evaluate and how optimistic are executives at the company.
Federal prosecutors claim a former DePuy Synthes sales representative defrauded an undisclosed Boston area hospital, with hundreds of thousands of dollars worth of spine products involved. Kirsh and Whooley share what the sales representative is accused of, how it allegedly benefitted the sales rep and DePuy Synthes' response.
The resignation of NeuroPace's CEO and the appointment of a former Integer executive as his successor mark a significant leadership change within the company. Whooley and Kirsh discuss the details behind the resignation and who is taking over the corner office.
Check out the show notes for links to the stories we discussed today at MassDevice.com/podcast.
More episodes of the podcast Fast Five Medtech News Podcast
Edwards reports new outcomes with TAVR; SafeGuard wins breakthrough nod for biodegradable stent
15/03/2024
Former Stimwave CEO convicted of healthcare fraud; GE HealthCare establishes charitable foundation
14/03/2024
iRhythm closes offering worth more than $660M; FDA accepts Onward BCI into advisory program
12/03/2024
Fast Five: FTC may look at Boston Scientific's Axonics buy, Roche unveils new AI-enabled CGM
08/03/2024
Fast Five: Haemonetics buys Attune Medical, Medtronic faces jury trial in spine implant suit
06/03/2024
ZARZA We are Zarza, the prestigious firm behind major projects in information technology.